Bing Xia

Johnson & Johnson (United States) — United States

Engineering · Physical Sciences

27h-index2.3kcitations206works3.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Nuclear reactor physics and engineering(22), Lung Cancer Treatments and Mutations(18), Nerve injury and regeneration(18), Nuclear Materials and Properties(18), Lung Cancer Research Studies(14)

Publications206 total

Heimdall++: Optimizing GPU Utilization and Pipeline Parallelism for Efficient Single-Pulse Detection
arXiv (Cornell University)·2025Open Access
Oncogenic EGFR rewires STING-TBK1 immune machinery by tyrosine phosphorylation to license DNA damage tolerance
2025Open Access
Bamboo‐Inspired Composite Conduit Accelerates Peripheral Nerve Regeneration through Synergistic Oriented Structure and Piezoelectricity
Advanced Materials·2025· 5 cited
The expression of GSTP1 in the filum terminale of children with tethered cord syndrome
Child s Nervous System·2025
Correction to “A Novel Superparamagnetic Multifunctional Nerve Scaffold: A Remote Actuation Strategy to Boost In Situ Extracellular Vesicles Production for Enhanced Peripheral Nerve Repair”
Advanced Materials·2025Open Access
Supplementary Figure S1 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025Open Access
Supplementary Table S1 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025Open Access
Supplementary Figure S4 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025Open Access
Supplementary Figure S5 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025Open Access
Supplementary Figure S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025Open Access
Supplementary Table S4 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025Open Access
Supplementary Table S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025Open Access
Supplementary Table S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025Open Access
Data from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025Open Access
Supplementary Figure S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025Open Access
Simulation of the HTR-PM’s operation history using the PANGU code
Progress in Nuclear Energy·2025· 3 cited
Correction: Galactin-8 DNA methylation mediates macrophage autophagy through the MAPK/mTOR pathway to alleviate atherosclerosis
Scientific Reports·2025Open Access
Refueling decision method in the PB-HTR based on the reactivity equilibrium equation
Progress in Nuclear Energy·2025· 1 cited
Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase Ⅱ study
Lung Cancer·2025· 1 citedOpen Access
[ATF3 regulates inflammatory response in atherosclerotic plaques in mice through the NF-κB signaling pathway].
PubMed·2025· 1 cited
page 1 of 11Next →

Frequent Co-authors

Jinghui Huang(14), Teng Ma(10), Zhuojing Luo(10), Liangliang Huang(9), Jianbo Gao(8), Huabin Cao(8), Guoliang Hu(8), Caiying Zhang(8), Shengyou Li(7), Valentine I. Vullev(7), Yujie Yang(6), Guilford Jones(6), Xiaobo Yang(6), Cheng Su(5), Kangcheng Chen(5), Yingnan Lv(5), Lei Zhu(4), Xiaowei Shi(4), Zhongyang Liu(4), Kai Luo(4)